North America cough suppressant market is predicted to point out good growth over the forecast period, due to frequent approvals to novel drugs by the FDA. As an example, in 2015, Vernalis PLC and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III).
Figure 1. Global Cough Suppressant Drugs Market Share (%) Analysis, By Region, 2026
Message Me to Request Sample copy
Figure 2. Global Cough Suppressant Drugs Market Share (%) Analysis, By channel, 2026
Various new players are entering lucrative cough suppressant drugs market by partnering with other manufacturers. As an example, in November 2018, Aytu BioScience, Inc., a specialty drug company, entered into the cough suppressant drugs market with an exclusive license of FDA-approved Tuzistra XR from Tris Pharma Inc. alongside Tuzistra XR, Aytu BioScience, Inc. also features a licensed complementary antitussive product with pending FDA approval.
Message Me to Request PDF Brochure
Key players operating within the global Cough Suppressant Drugs Market include Perrigo Company PLC, Vernalis PLC, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline PLC.
Edit your job
Opening message is automatically displayed as your first message in the order detail page.
There are no extra services
Welcome to Freelance Global Gigs.
Post your Gigs at Freelance Global Gigs - We have opportunities for everyone.